TESAMORELIN
Gs. 0
Skip to product information
TESAMORELIN
Tesamorelin is a synthetic 44-amino-acid peptide analog of Growth Hormone-Releasing Hormone (GHRH)[1]. It stimulates endogenous growth hormone release and raises IGF-1 levels, leading to enhanced lipolysis and metabolic benefits[2]. Tesamorelin is FDA-approved for reducing visceral adipose tissue in HIV-associated lipodystrophy and is studied for metabolic disorders and aging research[3][4].
- Reconstitute: Add 3.0 mL bacteriostatic water per 10 mg vial → ~3.33 mg/mL concentration.
- Standard daily dose: 2 mg (2000 mcg) once daily subcutaneously (FDA-approved protocol).
- Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
- Storage: Lyophilized & Reconstituted: refrigerate at 2–8 °C (35.6–46.4 °F)
| Week | Daily Dose (mg / mcg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 1 mg / 1000 mcg | 30 units (0.30 mL) |
| Weeks 2–12+ | 2 mg / 2000 mcg | 60 units (0.60 mL) |
Frequency: Inject once daily subcutaneously, preferably in the evening to coincide with nocturnal GH release[5][6]. The 2 mg daily dose is the standard FDA-approved regimen for HIV lipodystrophy[7][8]. A one-week titration at 1 mg may improve tolerability before advancing to the full 2 mg dose.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
